Laboratory Corporation of America Holdings operates in the competitive healthcare sector and has shown resilience with its comprehensive testing services and research capabilities. The company aims to push boundaries in both diagnostics and drug development, offering diverse opportunities for growth. With its extensive collaborations and technological advancements, LabCorp remains a crucial player in life sciences.
Current fundamental scores indicate a solid financial foundation with particular strengths in discounted cash flow and returns on equity and assets.
Category | Score | Visual |
---|---|---|
Discounted Cash Flow | 4 | |
Return on Equity | 4 | |
Return on Assets | 4 | |
Debt to Equity | 1 | |
Price to Earnings | 1 | |
Price to Book | 2 |
Review of historical performance shows consistent financial metrics with a slight improvement over time.
Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
---|---|---|---|---|---|---|---|
2025-05-30 | 3 | 4 | 4 | 4 | 1 | 1 | 2 |
(Prior) | N/A | 4 | 4 | 4 | 1 | 1 | 2 |
Analyst consensus shows a consistent price target, highlighting stable market expectations for LabCorp’s stock.
High | Low | Median | Consensus |
---|---|---|---|
$271 | $271 | $271 | $271 |
Majority of analysts have a positive outlook on Laboratory Corporation of America Holdings with a strong wave of 'Buy' ratings.
Recommendation | Count | Visual |
---|---|---|
Buy | 26 | |
Hold | 7 |
Laboratory Corporation of America Holdings represents a robust investment within the healthcare sector, with strong fundamental ratings hinting at financial stability and growth potential. The consensus among analysts is favorable, supported by consistent price targets. Despite potential risks related to market variability and debt ratio, the strength in testing services and strategic alliances enhances its market position. The stock's low Price to Earnings and positive analyst sentiment suggest an attractive valuation, warranting consideration for a long-term investment.